Phibro Animal Health (NASDAQ:PAHC) Stock Rating Upgraded by Zacks Research

Phibro Animal Health (NASDAQ:PAHC) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

Several other research analysts have also weighed in on the stock. JPMorgan Chase & Co. upped their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday. Bank of America upped their target price on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a research report on Friday, August 29th. Finally, Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research note on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $31.40.

Phibro Animal Health Trading Up 4.7%

Shares of PAHC opened at $40.09 on Tuesday. The firm has a market capitalization of $1.62 billion, a P/E ratio of 24.15, a PEG ratio of 1.08 and a beta of 0.77. Phibro Animal Health has a twelve month low of $16.16 and a twelve month high of $46.42. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32. The firm’s 50-day moving average is $41.16 and its two-hundred day moving average is $34.35.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The firm had revenue of $363.89 million during the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, research analysts predict that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Insider Transactions at Phibro Animal Health

In other news, CEO Jack Bendheim sold 1,288 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $40.19, for a total value of $51,764.72. Following the sale, the chief executive officer directly owned 44,952 shares of the company’s stock, valued at approximately $1,806,620.88. This trade represents a 2.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 147,824 shares of company stock worth $6,385,720 in the last three months. 50.13% of the stock is owned by corporate insiders.

Institutional Trading of Phibro Animal Health

Several hedge funds have recently added to or reduced their stakes in PAHC. Tudor Investment Corp ET AL grew its holdings in Phibro Animal Health by 3.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after buying an additional 338 shares during the last quarter. Danske Bank A S bought a new stake in shares of Phibro Animal Health in the third quarter valued at approximately $955,000. Advisory Services Network LLC acquired a new stake in shares of Phibro Animal Health in the third quarter worth $96,000. Dark Forest Capital Management LP bought a new position in Phibro Animal Health during the third quarter worth $2,751,000. Finally, Virtus Advisers LLC raised its stake in Phibro Animal Health by 922.9% during the 3rd quarter. Virtus Advisers LLC now owns 48,576 shares of the company’s stock valued at $1,965,000 after purchasing an additional 43,827 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.